Erratum: TET1 is a tumor suppressor of hematopoietic malignancy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

1. Disturbance of calcium homeostasis and myogenesis caused by TET2 deletion in muscle stem cells.Cell death discovery · 2022
   Article
2. Epigenetic alterations in stem cell ageing-a promising target for age-reversing interventions?Briefings in functional genomics · 2022
   Review
3. Epigenetic modifications in acute myeloid leukemia: The emerging role of circular RNAs (Review).International journal of oncology · 2021
   Review
4. Effect of cytostatic proline rich polypeptide-1 on tumor suppressors of inflammation pathway signaling in chondrosarcoma.Molecular and clinical oncology · 2016
   Article
5. Physiological and pathological implications of 5-hydroxymethylcytosine in diseases.Oncotarget · 2016
   Review

Corrections and comments

• Erratum for
  TET1 is a tumor suppressor of hematopoietic malignancy.2015

Authors and funding

19 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.